ProKidney Earnings Call Transcripts
Fiscal Year 2026
-
Rilparencel, an autologous cell therapy, is advancing through a pivotal phase III trial for advanced CKD, with top-line data expected in Q2 2027. Phase II results showed significant improvement in kidney function and strong safety, while manufacturing and commercial preparations are underway.
Fiscal Year 2025
-
The company is advancing an autologous cell therapy for advanced CKD, with phase III trials over 50% enrolled and an accelerated approval readout expected in Q2 2027. Strong phase II data, a robust safety profile, and significant market potential support commercial prospects.
-
The conference highlighted significant progress in the Phase III program for advanced CKD, including FDA alignment on accelerated approval using eGFR slope and a robust effect size. Financially, the company is well-funded through mid-2027, with a large addressable market and strong manufacturing capabilities.
-
Phase II data showed a significant reduction in kidney function decline with rilparencel, and detailed results will be presented at ASN Kidney Week. The phase III PROACT 1 trial is over 50% enrolled, targeting advanced CKD, with accelerated approval readout expected in Q2 2027.
-
A cell therapy for advanced CKD showed strong Phase II results, with a 78% improvement in eGFR decline and plans for accelerated approval based on a single Phase III trial. Manufacturing and commercial readiness are in place, with key data and regulatory updates expected in the next year.
-
Significant operational reset in 2024 led to resumed clinical programs and enhanced trial diversity. Phase 2 and interim phase 2b results show kidney function stabilization in high-risk patients, with a robust safety profile. Phase 3 pivotal trial is underway, with top-line results expected by end of 2027.
Fiscal Year 2024
-
Regulatory and clinical milestones are set for 2025, including key data from REGEN-007 and updates on the accelerated approval pathway. Focus remains on late-stage CKD patients, with manufacturing and financial resources in place to support progress through 2027.
-
Rilparencel, a cell therapy for advanced diabetic kidney disease, demonstrated kidney function stabilization in phase 2 trials and is now in a pivotal phase 3 study. FDA feedback allows a single trial for approval, with updates on accelerated pathways and new clinical data expected next year.
-
Rilparencel, an autologous cell therapy for advanced diabetic kidney disease, is advancing through a focused phase III program after regulatory and manufacturing improvements. FDA supports a single pivotal trial and accelerated approval using eGFR slope, with key data and regulatory milestones expected in 2025.
-
Rilparencel, an autologous cell therapy for advanced diabetic CKD, has shown promising efficacy and safety in phase II trials, leading to a focused phase III study with top-line results expected in 2027. Regulatory strategy leverages RMAT designation, and key data and updates are anticipated in 2025.
-
REACT, an autologous cell therapy for advanced diabetic kidney disease, showed promising phase II results with stabilization of kidney function and strong safety. The company is now focusing on a single U.S. phase III trial, leveraging regulatory flexibility and improved manufacturing to accelerate development.
-
Interim phase II REGEN-007 results show Rilparencel preserved kidney function in high-risk diabetic CKD patients, with an 18-month eGFR decline of -1.3 mL/min versus -6.2 mL/min in matched controls. Safety was consistent with prior studies, and phase III trials are underway.